BioCryst Pharmaceuticals (BCRX) Competitors $8.47 -0.05 (-0.59%) Closing price 04:00 PM EasternExtended Trading$8.45 -0.02 (-0.24%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX vs. RGEN, IONS, ALKS, LGND, FOLD, CLDX, INVA, NVAX, DVAX, and MNKDShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Repligen (RGEN), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), and MannKind (MNKD). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Its Competitors Repligen Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Innoviva Novavax Dynavax Technologies MannKind BioCryst Pharmaceuticals (NASDAQ:BCRX) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Which has preferable earnings & valuation, BCRX or RGEN? Repligen has higher revenue and earnings than BioCryst Pharmaceuticals. Repligen is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$450.71M3.94-$88.88M-$0.18-47.06Repligen$634.44M10.83-$25.51M-$0.25-488.68 Do analysts rate BCRX or RGEN? BioCryst Pharmaceuticals presently has a consensus price target of $16.70, suggesting a potential upside of 97.17%. Repligen has a consensus price target of $169.45, suggesting a potential upside of 38.70%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Repligen 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Which has more volatility & risk, BCRX or RGEN? BioCryst Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Does the media favor BCRX or RGEN? In the previous week, Repligen had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 15 mentions for Repligen and 6 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.51 beat Repligen's score of 1.33 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Repligen 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BCRX or RGEN more profitable? Repligen has a net margin of -2.05% compared to BioCryst Pharmaceuticals' net margin of -6.41%. Repligen's return on equity of 4.61% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-6.41% N/A -1.78% Repligen -2.05%4.61%3.24% Do insiders & institutionals have more ownership in BCRX or RGEN? 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryBioCryst Pharmaceuticals and Repligen tied by winning 8 of the 16 factors compared between the two stocks. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.79B$2.51B$5.78B$9.80BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-47.0522.8231.2626.59Price / Sales3.94733.81464.64173.43Price / CashN/A177.0937.7359.36Price / Book-4.216.1810.046.68Net Income-$88.88M$32.94M$3.27B$265.59M7 Day Performance1.07%0.99%3.17%3.42%1 Month Performance2.54%1.69%4.34%1.09%1 Year Performance-0.94%11.44%44.12%23.84% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.1583 of 5 stars$8.47-0.6%$16.70+97.2%+3.5%$1.79B$450.71M-47.05530Positive NewsRGENRepligen4.8584 of 5 stars$121.26-2.8%$169.45+39.7%-18.6%$6.82B$634.44M-485.021,778Positive NewsIONSIonis Pharmaceuticals4.6124 of 5 stars$41.82-2.0%$60.92+45.7%-11.6%$6.67B$705M-22.731,069News CoverageAnalyst ForecastOptions VolumeAnalyst RevisionALKSAlkermes4.6713 of 5 stars$29.00-2.5%$41.08+41.7%+3.8%$4.79B$1.56B13.941,800LGNDLigand Pharmaceuticals4.0888 of 5 stars$158.79-0.2%$157.00-1.1%+49.6%$3.11B$167.13M-39.7080Positive NewsAnalyst ForecastFOLDAmicus Therapeutics4.3122 of 5 stars$7.48-1.7%$16.22+116.9%-33.2%$2.31B$528.29M-62.33480Positive NewsCLDXCelldex Therapeutics1.845 of 5 stars$21.93-2.4%$46.67+112.8%-40.8%$1.46B$7.02M-7.29150News CoverageINVAInnoviva4.4843 of 5 stars$19.76-2.0%$42.75+116.3%+3.8%$1.25B$358.71M63.74100Positive NewsNVAXNovavax4.5408 of 5 stars$7.52-4.1%$15.57+107.1%-32.0%$1.22B$682.16M3.301,990News CoverageAnalyst ForecastGap UpDVAXDynavax Technologies4.6929 of 5 stars$10.39-1.0%$24.33+134.2%-8.5%$1.22B$277.25M-22.59350MNKDMannKind3.2807 of 5 stars$3.90-5.1%$9.71+149.1%-16.0%$1.20B$301.74M35.46400News CoverageAnalyst ForecastGap DownHigh Trading Volume Related Companies and Tools Related Companies RGEN Competitors IONS Competitors ALKS Competitors LGND Competitors FOLD Competitors CLDX Competitors INVA Competitors NVAX Competitors DVAX Competitors MNKD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCRX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access